Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330042 · ClinicalTrials.gov registry record
OCT Biomarkers for Diabetic Retinopathy
A clinical trial of Diabetic Retinopathy, sponsored by Oregon Health and Science University.
- Active
- Registry status
- 165
- Enrollment target
- 1
- Study location
NCT02330042: Active study of Diabetic Retinopathy, sponsored by Oregon Health and Science University.
NCT02330042 is a study of Diabetic Retinopathy that is active but no longer recruiting, run by Oregon Health and Science University. The registered enrollment target is 165 participants, below the 1,674-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02330042, a study of Diabetic Retinopathy, is active but no longer recruiting, sponsored by Oregon Health and Science University.
- ACTIVE NOT RECRUITING
- Registry status
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
Diabetic retinopathy (DR) is caused by changes in the blood vessels of the retina associated with long-term Type 1 or Type 2 diabetes mellitus. DR is a leading cause of blindness in the United States. Standard optical coherence tomography (OCT) cannot directly detect vascular changes, which may occur early affecting the passage of blood through the tiny capillaries (reduced capillary flow) or cause the greatest damage through formation of abnormal blood vessel growth (neovascularization). Currently, fluorescein angiography (FA) is the gold standard for detecting these changes, but FA requires an injection of a dye into the vein of the arm of the patient. This dye can cause undesirable side effects. Recently, OCT has been used to make functional measurements (such as total retinal blood flow among others) and to perform angiography. Thus, functional OCT may provide a useful, alternate way to evaluate diabetic retinopathy.
Primary Outcome
Total retinal blood flow will be measured in uL/min.
Conditions Studied
Study Locations (1)
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2015-01-26 |
| Est. Completion | 2026-12 |
What the registry record for NCT02330042 still lists
NCT02330042 is an observational study that tracks outcomes without assigning an intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 1,674-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 0 interventions.
NCT02330042 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT02330042 about?
NCT02330042 is a clinical study titled "OCT Biomarkers for Diabetic Retinopathy". Diabetic retinopathy (DR) is caused by changes in the blood vessels of the retina associated with long-term Type 1 or Type 2 diabetes mellitus. DR is a leading cause of blindness in the United States. Standard optical coherence tomography (OCT) cannot directly detect vascular changes, which may occu...
What is the current status of trial NCT02330042?
This trial is currently active not recruiting. The enrollment target is 165 participants. The study started on 2015-01-26. Estimated completion is 2026-12.
What conditions does trial NCT02330042 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
Who is sponsoring clinical trial NCT02330042?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02330042 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02330042's enrollment target sits among peer trials
165 31st of 57 higher than 27 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
RECRUITING
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI